Mannkind reported $39.35M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Adma Biologics ADMA:US $ 16.94M 33.64M
Biocryst Pharmaceuticals BCRX:US $ 100.25M 374K
Chemocentryx CCXI:US $ 43.34M 355K
Dynavax Technologies DVAX:US $ 128.24M 45.01M
Eli Lilly And LLY:US $ 5277.9M 127.8M
Halozyme Therapeutics HALO:US $ 118.3M 76.7M
Immunogen IMGN:US $ 75.22M 14.28M
Insmed INSM:US $ 153.54M 10.6M
JAZZ PHA JAZZ:US $ 847.33M 121.16M
Karyopharm Therapeutics KPTI:US $ 82.59M 331K
Macrogenics MGNX:US $ 67.82M 9.92M
Mannkind MNKD:US $ 39.35M 6.1M
Merk MRK:US $ 9666M 666M
Minerva Neurosciences NERV:US $ 6.97M 1.02M
Novavax NVAX:US $ 668.88M 174.21M
Novo Nordisk A Fs NVO:US 22.87B 10M
Peregrine Pharmaceuticals PPHM:US $ 33.96M 3.8M
Pfizer PFE:US $ 15640M 148M
Xencor XNCR:US $ 58.18M 854K